Skip to main navigation Skip to search Skip to main content

A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis

  • Stephen A. Harrison
  • , Mustafa R. Bashir
  • , Kyoung Jin Lee
  • , Jennifer Shim-Lopez
  • , Jonathan Lee
  • , Brandee Wagner
  • , Nicholas D. Smith
  • , Hubert C. Chen
  • , Eric J. Lawitz

Research output: Contribution to journal › Article › peer-review

124   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology